Completed PHASE3 INTERVENTIONAL 4-arm NCT01327846

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events) (CANTOS)

A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP

Sponsor: Novartis Pharmaceuticals

Conditions Atherosclerosis

Interventions Canakinumab Placebo Standard of care

Updated 22 times since 2017 Last updated: Jan 10, 2020 Started: Apr 11, 2011 Primary completion: Mar 28, 2017 Completion: Apr 14, 2019

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Atherosclerosis, this trial is completed. The trial is conducted by Novartis Pharmaceuticals and has accumulated 22 data snapshots since 2011. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

22 versions recorded

Feb 2026 — Present [monthly]

Completed PHASE3
Dec 2025 — Feb 2026 [monthly]

Completed PHASE3
Nov 2025 — Dec 2025 [monthly]

Completed PHASE3
Sep 2025 — Nov 2025 [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3

▶ Show 17 earlier versions

Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Oct 2022 — Jul 2024 [monthly]

Completed PHASE3
Sep 2022 — Oct 2022 [monthly]

Completed PHASE3
Dec 2021 — Sep 2022 [monthly]

Completed PHASE3
Jan 2021 — Dec 2021 [monthly]

Completed PHASE3
Feb 2020 — Jan 2021 [monthly]

Completed PHASE3

Status: Active Not Recruiting → Completed
Feb 2019 — Feb 2020 [monthly]

Active Not Recruiting PHASE3
Dec 2018 — Feb 2019 [monthly]

Active Not Recruiting PHASE3
Sep 2018 — Dec 2018 [monthly]

Active Not Recruiting PHASE3
Jun 2018 — Sep 2018 [monthly]

Active Not Recruiting PHASE3
Apr 2018 — Jun 2018 [monthly]

Active Not Recruiting PHASE3
Feb 2018 — Apr 2018 [monthly]

Active Not Recruiting PHASE3

Status: Recruiting → Active Not Recruiting
Jan 2018 — Feb 2018 [monthly]

Recruiting PHASE3
Dec 2017 — Jan 2018 [monthly]

Recruiting PHASE3

Status: Active Not Recruiting → Recruiting
May 2017 — Dec 2017 [monthly]

Active Not Recruiting PHASE3
Feb 2017 — May 2017 [monthly]

Active Not Recruiting PHASE3
Jan 2017 — Feb 2017 [monthly]

Active Not Recruiting PHASE3

First recorded

Apr 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Novartis Pharmaceuticals

Data source: Novartis

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aalst, Belgium , Abington, United States , Aguascalientes, Mexico , Ahmedabad, India , Akron, United States , Alberton, South Africa , Albuquerque, United States , Alkmaar, Netherlands , Allen, United States , Altoona, United States and 808 more locations